Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial

Similar Items

• Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial
  by: Bosch J.; Eikelboom J.W.; Connolly S.J.; Bruns N.C.; Lanius V.; Yuan F.; Misselwitz F.; Chen E.; Diaz R.; Alings M.; Lonn E.M.; Widimsky P.; Hori M.; Avezum A.; Piegas L.S.; Bhatt D.L.; Branch K.R.H.; Probstfield J.L.; Liang Y.; Liu L.; Zhu J.; Maggioni A.P.; Lopez-Jaramillo P.; O'Donnell M.; Fox K.A.A.; Kakkar A.; Parkhomenko A.N.; Ertl G.; Störk S.; Keltai K.; Keltai M.; Ryden L.; Dagenais G.R.; Pogosova N.; Dans A.L.; Lanas F.; Commerford P.J.; Torp-Pedersen C.; Guzik T.J.; Verhamme P.B.; Vinereanu D.; Kim J.-H.; Ha J.-W.; Tonkin A.M.; Varigos J.D.; Lewis B.S.; Felix C.; Yusoff K.; Steg P.G.; Aboyans V.; Metsarinne K.P.; Anand S.S.; Hart R.G.; Lamy A.; Moayyedi P.; Leong D.P.; Sharma M.; Yusuf S.
  Published: (2017)
• Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics
  by: Lonn E.; Bosch J.; Pogue J.; Avezum A.; Chazova I.; Dans A.; Diaz R.; Fodor G.J.; Held C.; Jansky P.; Keltai M.; Keltai K.; Kunti K.; Kim J.-H.; Leiter L.; Lewis B.; Liu L.; Lopez-Jaramillo P.; Pais P.; Parkhomenko A.; Peters R.J.G.; Piegas L.S.; Reid C.M.; Sliwa K.; Toff W.D.; Varigos J.; Xavier D.; Yusoff K.; Zhu J.; Dagenais G.; Yusuf S.
  Published: (2016)
• Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
  by: Moayyedi P.; Eikelboom J.W.; Bosch J.; Connolly S.J.; Dyal L.; Shestakovska O.; Leong D.; Anand S.S.; Störk S.; Branch K.R.H.; Bhatt D.L.; Verhamme P.B.; O'Donnell M.; Maggioni A.P.; Lonn E.M.; Piegas L.S.; Ertl G.; Keltai M.; Bruns N.C.; Muehlhofer E.; Dagenais G.R.; Kim J.-H.; Hori M.; Steg P.G.; Hart R.G.; Diaz R.; Alings M.; Widimsky P.; Avezum A.; Probstfield J.; Zhu J.; Liang Y.; Lopez-Jaramillo P.; Kakkar A.K.; Parkhomenko A.N.; Ryden L.; Pogosova N.; Dans A.L.; Lanas F.; Commerford P.J.; Torp-Pedersen C.; Guzik T.J.; Vinereanu D.; Tonkin A.M.; Lewis B.S.; Felix C.; Yusoff K.; Metsarinne K.P.; Fox K.A.A.; Yusuf S.
  Published: (2019)
• Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial
  by: Moayyedi P.; Eikelboom J.W.; Bosch J.; Connolly S.J.; Dyal L.; Shestakovska O.; Leong D.; Anand S.S.; Störk S.; Branch K.R.H.; Bhatt D.L.; Verhamme P.B.; O'Donnell M.; Maggioni A.P.; Lonn E.M.; Piegas L.S.; Ertl G.; Keltai M.; Cook Bruns N.; Muehlhofer E.; Dagenais G.R.; Kim J.-H.; Hori M.; Steg P.G.; Hart R.G.; Diaz R.; Alings M.; Widimsky P.; Avezum A.; Probstfield J.; Zhu J.; Liang Y.; Lopez-Jaramillo P.; Kakkar A.; Parkhomenko A.N.; Ryden L.; Pogosova N.; Dans A.; Lanas F.; Commerford P.J.; Torp-Pedersen C.; Guzik T.; Vinereanu D.; Tonkin A.M.; Lewis B.S.; Felix C.; Yusoff K.; Metsarinne K.; Fox K.A.A.; Yusuf S.
  Published: (2019)
• Reconsidering terms for mechanisms of polymer growth: the “step-growth” and “chain-growth” dilemma
  by: Chan C.H.; Chen J.-T.; Farrell W.S.; Fellows C.M.; Keddie D.J.; Luscombe C.K.; Matson J.B.; Merna J.; Moad G.; Russell G.T.; Théato P.; Topham P.D.; Sosa Vargas L.
  Published: (2022)